Enterprise Value
-61.94M
Cash
137.2M
Avg Qtr Burn
-10.13M
Short % of Float
0.96%
Insider Ownership
11.91%
Institutional Own.
75.68%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CYT-0851 w/ gemcitabine Details Solid tumor/s, Cancer | Phase 1 Data readout | |
CYT-0851 w/ capecitabine Details Cancer, Ovarian cancer | Phase 1 Interim update |